Disease Research

Stock Quotes for Disease Research top ^
  • Industry: Diagnostics & Research
  • Sector: Healthcare
Sign-up for htds investment picks

News Articles for Disease Research top ^
Today, Lundbeck and the Hereditary Disease Foundation announced the launch of the fifth annual Build Hope for Huntington’s Disease (HD) initiative.
Sign-up for Lundbeck Partners with the Hereditary Disease Foundation, Pledges Five Additional Years of Support for Build Hope for Huntington’s Disease Campaign investment picks
The Medicines Company (NASDAQ:MDCO) today announced that data from its infectious disease portfolio will be presented at ID Week 2014, October 8-12 in Philadelphia, Pennsylvania.
Sign-up for The Medicines Company Infectious Disease Portfolio Data to Be Presented at ID Week 2014 investment picks
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder (CKD-MBD) with Ravi Thadhani, M.D., M.P.H. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept in patients with end-stage renal disease with mineral and bone disorder.
Sign-up for Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder investment picks
Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.
Sign-up for Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform investment picks
More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms i of peripheral arterial disease (PAD). However, the majority are unfamiliar with the disease and relatively few who experience symptoms see a doctor, according a recent online awareness survey conducted by Harris Poll.
Sign-up for Survey Shows 43 Percent of Americans Ages 40 and Older Have Experienced Symptoms of Peripheral Arterial Disease (PAD) investment picks
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA ® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Sign-up for Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults investment picks
A national survey from Rite Aid (NYSE: RAD) and National Foundation for Infectious Diseases (NFID) reveals that the majority of adult women living in the United States do not believe they are up to date on vaccinations to protect against many preventable diseases.
Sign-up for Rite Aid and National Foundation for Infectious Diseases Survey Indicates Most U.S. Women Believe They Are Not Up To Date on Vaccinations investment picks
-- Enrollment achieved in first two dose cohorts of Phase 1/2 Waldenstrom's trial -- Myositis program advanced with specification of Phase 2 clinical trial plan in dermatomyositis --
Sign-up for Idera Pharmaceuticals Reports Third Quarter Financial Results and Announces Expansion of Rare Disease Development Portfolio investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that detailed results from its Phase 2 study of GCS-100 in chronic kidney disease (CKD) patients are being presented at a poster session ( Glomerular and Tubulointerstitial Disease: Clinical Trials and Outcomes , November 13, 10:00 a.m. - 12:00 p.m. Eastern Standard Time, Poster TH-PO460 ) at the American Society of Nephrology’s (ASN) Kidney Week Annual Meeting.
Sign-up for Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week investment picks
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID™ (pimavanserin) for Parkinson’s disease psychosis (PDP) at the 10 th Annual International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders held from December 5-7 in Nice, France.
Sign-up for ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders investment picks
EYEGUARD-US is a randomized withdrawal study, conducted at U.S. clinical sites, to determine the efficacy and safety of gevokizumab in treating Behçet's disease uveitis patients Study is open to Behçet's disease uveitis patients experiencing an ocular inflammatory episode or patients whose ocular inflammation currently is controlled BERKELEY, Calif., Sept.
Sign-up for XOMA Initiates U.S. Clinical Trial of Gevokizumab in Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US investment picks
--Study Demonstrated Clinically Meaningful and Statistically Significant Improvement of Agitation in Patients with Alzheimer's Disease--
Sign-up for Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting investment picks
Immune Pharmaceuticals Recently Initiated Phase II Clinical Trial in Ulcerative Colitis CAMBRIDGE, Mass.
Sign-up for New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease investment picks
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease.
Sign-up for Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease investment picks
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate --
Sign-up for AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that 25 abstracts reporting the results of hepatitis C virus (HCV) treatment regimens containing ABT-450, Enanta’s lead protease inhibitor, or ABT-493, Enanta’s next-generation protease inhibitor, have been accepted for presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 7-11, 2014 in Boston, MA.
Sign-up for Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing ABT-450 or ABT-493 to be Presented at the American Association for the Study of Liver Diseases (AASLD) investment picks
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with severe sickle cell disease has undergone infusion with bluebird bio’s LentiGlobin BB305 drug product in an autologous hematopoietic stem cell transplantation.
Sign-up for bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy investment picks
BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels BI1181181/VTP-37948 Was Safe and Generally Well-Tolerated With a Profile Supporting Once-Daily Dosing FORT WASHINGTON, Pa., Oct.
Sign-up for Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.


Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Disease Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Discussing Financial Results  |  Next: Disney Consumer Products